BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31711889)

  • 1. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
    Merz LE; Perissinotti AJ; Marini BL; Burke PW; Crouch A; Erba HP; Bixby D
    Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):24-30. PubMed ID: 31711889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.
    Sitges M; Boluda B; Garrido A; Morgades M; Granada I; Barragan E; Arnan M; Serrano J; Tormo M; Miguel Bergua J; Colorado M; Salamero O; Esteve J; Benavente C; Pérez-Encinas M; Coll R; Martí-Tutusaus JM; Brunet S; Sierra J; Ángel Sanz M; Montesinos P; Ribera JM; Vives S;
    Eur J Haematol; 2020 Aug; 105(2):138-147. PubMed ID: 32243655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study.
    Gong X; Yu T; Tang Q; Fu Y; Wu J; Zhu Y; Tu H; Ge H; Lu X; Gong D; Zhao X
    Int J Lab Hematol; 2019 Jun; 41(3):380-386. PubMed ID: 30793839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
    Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
    Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
    Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
    Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
    Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study.
    Liu D; Wang X; Tong J; Zhou L; Chen E; Zhou Z; Xue L; Zhang X; Sun G; Zheng C
    Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676738
    [No Abstract]   [Full Text] [Related]  

  • 13. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
    Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
    Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
    Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
    Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
    Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
    Richard-Carpentier G; Rausch CR; Sasaki K; Hammond D; Morita K; Takahashi K; Tang G; Kanagal-Shamanna R; Bhalla K; Dinardo CD; Borthakur G; Pemmaraju N; Shpall EJ; Alousi A; Daver NG; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM; Kadia TM
    Haematologica; 2023 Sep; 108(9):2331-2342. PubMed ID: 36951163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
    J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features.
    Testoni N; Borsaru G; Martinelli G; Carboni C; Ruggeri D; Ottaviani E; Pelliconi S; Ricci P; Pastano R; Visani G; Zaccaria A; Tura S
    Haematologica; 1999 Aug; 84(8):690-4. PubMed ID: 10457403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.
    Ball B; Komrokji RS; Adès L; Sekeres MA; DeZern AE; Pleyer L; Vey N; Almeida A; Germing U; Cluzeau T; Platzbecker U; Gore SD; Fenaux P; Prebet T
    Blood Adv; 2018 Aug; 2(16):2063-2071. PubMed ID: 30120104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
    Brune MM; Stüssi G; Lundberg P; Vela V; Heim D; Manz MG; Haralambieva E; Pabst T; Banz Y; Bargetzi M; Grobholz R; Fehr M; Cogliatti S; Ossenkoppele GJ; Löwenberg B; Rudolf CB; Li Q; Passweg J; Mazzuchelli L; Medinger M; Tzankov A;
    Ann Hematol; 2021 May; 100(5):1169-1179. PubMed ID: 33704530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.